Log in

NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Forecast & News

-0.06 (-0.93 %)
(As of 12/15/2019 01:31 AM ET)
Today's Range
Now: $6.40
50-Day Range
MA: $6.17
52-Week Range
Now: $6.40
Volume1.15 million shs
Average Volume1.71 million shs
Market Capitalization$572.93 million
P/E RatioN/A
Dividend YieldN/A
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BDSI



Sales & Book Value

Annual Sales$55.64 million
Book Value$0.42 per share


Net Income$-33,870,000.00


Market Cap$572.93 million
Next Earnings Date3/12/2020 (Estimated)

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.34. The specialty pharmaceutical company had revenue of $30.31 million for the quarter, compared to analyst estimates of $28.86 million. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. View BioDelivery Sciences International's Earnings History.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for BioDelivery Sciences International.

What guidance has BioDelivery Sciences International issued on next quarter's earnings?

BioDelivery Sciences International issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$105-110 million, compared to the consensus revenue estimate of $$107.26 million.

What price target have analysts set for BDSI?

6 brokers have issued 1-year price objectives for BioDelivery Sciences International's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.

What is the consensus analysts' recommendation for BioDelivery Sciences International?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. According to Zacks Investment Research, "BioDelivery reported encouraging first-quarter results wherein earnings and sales surpassed the respective estimates. The company secured improved positioning in several managed care contracts, providing preferred access to Belbuca. The company’s efforts have brought 115 million patients under preferred coverage so far in 2019, having started 2018 with 7 million. The company’s efforts boosted the drug’s sales and the momentum is expected to continue in 2019. Belbuca’s prescriptions grew sequentially in the past few quarters. The acquisition of U.S. rights of Symproic strengthened the chronic pain portfolio. BioDelivery’s shares have outperformed the industry so far this year. However, given the lackluster performance of Bunavail, BioDelivery has decided to reduce spending on the drug. The company’s portfolio and its pipeline may face severe competition as these target a highly genericized and crowded market." (5/21/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post BDSI’s recent acquisition of U.S. commercial rights to Symproic, and equity raise, we are updating our model and reiterating our Overweight rating and 12-month price target of $8. BDSI has built a strong commercial team around Belbuca, and the acquisition leverages the company’s commercial strengths, and footprint, to grow its portfolio. We view the acquisition of Symproic as a positive as it diversifies the company’s revenue away from a single product, Belbuca, and can add a meaningful revenue contribution of $75MM + without the need for any significant increase in spending." (4/16/2019)
  • 3. HC Wainwright analysts commented, "Our $6 12-month target (from $5) is based on a DCF reflecting strong Belbuca growth to nearly $180M by 2022, company cash-flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10% WACC discount and negative -15% terminal value beyond 2026, and includes 90M fully diluted shares vs. currently reported 70M) to account for, among other shares, the substantial dilution from convertible preferred series B shares that were issued in the 2018 $50M financing ($1.80/share conversion price)." (3/15/2019)

Has BioDelivery Sciences International been receiving favorable news coverage?

Press coverage about BDSI stock has trended extremely negative on Sunday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for BioDelivery Sciences International.

Are investors shorting BioDelivery Sciences International?

BioDelivery Sciences International saw a decline in short interest in the month of November. As of November 29th, there was short interest totalling 2,830,000 shares, a decline of 7.8% from the November 14th total of 3,070,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 2.5 days. Approximately 3.5% of the company's stock are sold short. View BioDelivery Sciences International's Current Options Chain.

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), Exelixis (EXEL) and Sorrento Therapeutics (SRNE).

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:
  • Mr. Herm Cukier, CEO & Director (Age 52)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 58)
  • Mr. Ernest Robert De Paolantonio CPA, MBA, Exec. Officer (Age 66)

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (2.33%), Emerald Mutual Fund Advisers Trust (2.17%), State Street Corp (1.71%), 1492 Capital Management LLC (0.87%), Mackay Shields LLC (0.68%) and Squarepoint Ops LLC (0.57%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Paolantonio Ernest Robert De and Scott M Plesha. View Institutional Ownership Trends for BioDelivery Sciences International.

Which institutional investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Millennium Management LLC, Essex Investment Management Co. LLC, Barclays PLC and 1492 Capital Management LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo and Scott M Plesha. View Insider Buying and Selling for BioDelivery Sciences International.

Which institutional investors are buying BioDelivery Sciences International stock?

BDSI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Mackay Shields LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Systematic Financial Management LP, Brinker Capital Inc., Nisa Investment Advisors LLC and Metropolitan Life Insurance Co NY. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $6.40.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $572.93 million and generates $55.64 million in revenue each year. The specialty pharmaceutical company earns $-33,870,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. BioDelivery Sciences International employs 164 workers across the globe.View Additional Information About BioDelivery Sciences International.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is http://www.bdsi.com/.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  501 (Vote Outperform)
Underperform Votes:  307 (Vote Underperform)
Total Votes:  808
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel